| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Focal Dystonia | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Dystonia | |||||
| Dystonic Disorders | |||||
| 3 | More general conditions related to this trial | ||||
| Central Nervous System Diseases | |||||
| Dyskinesias | |||||
| Movement Disorders | |||||
| Nervous System Diseases | |||||
| Neurologic Manifestations | |||||
| Signs and Symptoms | |||||
| 4 | Interventions listed in this trial | ||||
| Amlodipine plus Botulinum toxin | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Amlodipine | |||||
| Botulinum Toxins | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Dyskinesia Agents | |||||
| Antihypertensive Agents | |||||
| Calcium Channel Blockers | |||||
| Cardiovascular Agents | |||||
| Central Nervous System Agents | |||||
| Membrane Transport Modulators | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| Vasodilator Agents | |||||
| 7 | Sponsors listed in this trial | ||||
| National Institute of Neurological Disorders and Stroke (NINDS) | |||||
|
